DU145 Xenograft Model Service for Prostate Cancer

The DU145 cell line provides a robust and well-characterized in vivo platform for investigating the molecular drivers and therapeutic vulnerabilities of androgen-independent prostate cancer. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision DU145 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of DU145 Xenograft Model for Prostate Cancer

The DU145 xenograft model is an established in vivo translational system widely utilized in oncology research for the study of advanced, androgen-independent prostate carcinoma. By transplanting human DU145 cells into immunodeficient rodent hosts, this model effectively reproduces the solid tumor growth characteristics, histopathological architecture, and proliferative patterns typical of human prostate malignancies that have progressed beyond androgen sensitivity.

Biologically, the DU145 model is highly valued for its moderate metastatic potential and its ability to grow reliably in castrated hosts, making it an excellent system for studying mechanisms of therapeutic resistance and tumor progression. This model retains essential phenotypic features of advanced carcinoma, including high proliferative rates and responsiveness to diverse pharmacological interventions. Consequently, the DU145 model is extensively deployed in pre-clinical screening programs to assess the anti-tumor potency of novel small-molecule inhibitors, targeted biological therapies, and combination treatment regimens in a physiologically relevant in vivo setting.

Fig 1. Formulation strategy of peptide:siRNA nanoparticles for GRP78 silencing activity in the DU145 prostate cancer cells. (Hilan G, et al., 2025)

Cell Line Information: DU145

The DU145 cell line is derived from a metastatic site (brain) of human prostate carcinoma. These cells exhibit stable, androgen-independent growth characteristics in vitro, making them a preferred choice for studying the aggressive behaviors and therapeutic efficacy in advanced pre-clinical prostate cancer models.

Our Services

Workflow of DU145 Xenograft Model Construction

• Cell Culture & Quality Control: Human DU145 cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability DU145 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take efficiency. Cells are inoculated in vivo via subcutaneous injection into the host flank to facilitate the development of a measurable, solid tumor.
• Longitudinal Monitoring: Tumor size is measured systematically using digital calipers to monitor volume progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into matched cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. DU145 Xenograft Model Construction Workflow

Case Study - DU145 Xenograft Model Development

A pre-clinical validation study was conducted using the DU145 xenograft model to evaluate the therapeutic efficacy of a novel small-molecule inhibitor targeting advanced prostate carcinoma. Following the successful subcutaneous inoculation of DU145 cells into immunodeficient mice, the host animals developed firm, rapidly expanding solid tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel prostate cancer interventions.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our DU145 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.